Migraine headache: When to consider these newer agents

,; ,; ,

doi:doi: 10.12788/jfp.0657

Applied Evidence

Migraine headache: When to consider these newer agents

J Fam Pract. 2023 September;72(7):292-303 | doi: 10.12788/jfp.0657

PDF Download

References

1. Lipton RB, Nicholson RA, Reed ML, et al. Diagnosis, consultation, treatment, and impact of migraine in the US: results of the OVERCOME (US) study. Headache. 2022;62:122-140. doi: 10.1111/head.14259

2. Burstein R, Noseda R, Borsook D. Migraine: multiple processes; complext pathophysiology. J Neurosci. 2015;35:6619-6629. doi: 10.1523/JNEUROSCI.0373-15.2015

3. Edvinsson L, Haanes KA, Warfvinge K, et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018;14:338-350. doi: 10.1038/s41582-018-0003-1

4. McGrath K, Rague A, Thesing C, et al. Migraine: expanding our Tx arsenal. J Fam Pract. 2019;68:10-14;16-24.

5. Dodick DW. Migraine. Lancet. 2018;391:1315-1330. doi: 10.1016/S0140-6736(18)30478-1

6. Agostoni EC, Barbanti P, Calabresi P, et al. Current and emerging evidence-based treatment options in chronic migraine: a narrative review. J Headache Pain. 2019;20:92. doi: 10.1186/s10194-019-1038-4

7. IHS. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211. doi: 10.1177/0333102417738202

8. Do TP, Remmers A, Schytz HW, et al. Red and orange flags for secondary headaches in clinical practice: SNNOOP10 list. Neurology. 2019;92:134-144. doi: 10.1212/WNL.0000000000006697

9. NIH. Migraine. Accessed July 30, 2023. www.ninds.nih.gov/health-information/disorders/migraine

10. AHS. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59:1-18. doi: 10.1111/head.13456

11. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American Headache Society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3-20. doi: 10.1111/head.12499

12. Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018;97:243-251.

13. Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache. 2015;55(suppl 4):221-235. doi: 10.1111/head.12601

14. Becker WJ. Acute migraine treatment. Continuum (Minneap Minn). 2015;21:953-972. doi: 10.1212/CON.0000000000000192

15. Migranal (dihydroergotamine mesylate) Package insert. Valeant Pharmaceuticals North America; 2019. Accessed June 17, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2019/020148Orig1s025lbl.pdf

16. Minen MT, Tanev K, Friedman BW. Evaluation and treatment of migraine in the emergency department: a review. Headache. 2014;54:1131-45. doi: 10.1111/head.12399

17. Durham PL. CGRP-receptor antagonists--a fresh approach to migraine therapy? N Engl J Med. 2004;350:1073-1075. doi: 10.1056/NEJMp048016

18. Ubrelvy (ubrogepant). Package insert. Allergan, Inc.; 2019. Accessed June 19, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2019/211765s000lbl.pdf

19. Nurtec ODT (rimegepant sulfate). Package insert. Biohaven Pharmaceuticals, Inc.; 2021. Accessed June 19, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2021/212728s006lbl.pdf

20. Zavzpret (zavegepant). Package insert. Pfizer Labs.; 2023. Accessed July 15, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2023/216386s000lbl.pdf

21. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381:2230-2241. doi: 10.1056/NEJMoa1813049

22. Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322:1887-1898. doi: 10.1001/jama.2019.16711

23. Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394:737-745. doi: 10.1016/S0140-6736(19)31606-X

24. Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22:209-217. doi: 10.1016/S1474-4422(22)00517-8

25. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant, an acute treatment for migraine, improved patient-reported functional disability and satisfaction in 2 single-attack phase 3 randomized trials, ACHIEVE I and II. Headache. 2020;60:686-700. doi: 10.1111/head.13766

26. Burch R. Migraine and tension-type headache: diagnosis and treatment. Med Clin North Am. 2019;103:215-233. doi:10.1016/j.mcna.2018.10.003

27. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337-1345. doi: 10.1212/WNL.0b013e3182535d20

28. Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia. 2019;39:445-458. doi: 10.1177/ 0333102418821662

29. Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ. 2010;182:E269-276. doi: 10.1503/cmaj.081657

30. Vyepti (eptinezumab-jjmr). Package insert. Lundbeck Pharmaceuticals LLV; 2020. Accessed June 19, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2020/761119s000lbl.pdf

31. Aimovig (erenumab-aooe). Package insert. Amgen Inc.; 2021. Accessed June 19, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2021/761077s009lbl.pdf

32. Ajovy (fremanezumab-vfrm). Package insert. Teva Pharmaceuticals USA, Inc.; 2018. Accessed June 19, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2018/761089s000lbl.pdf

33. Emgality (galcanezumab-gnlm). Package insert. Eli Lilly and Company; 2018. Accessed June 19, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2018/761063s000lbl.pdf

34. Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40:241-254. doi: 10.1177/0333102420905132

35. Lipton RB, Goadsby PJ, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology. 2020;94:e1365-e1377. doi: 10.1212/WNL.0000000000009169

36. Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38:1026-1037. doi: 10.1177/0333102418759786

37. Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377:2123-2132. doi: 10.1056/NEJMoa1705848

38. Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392:2280-2287. doi: 10.1016/S0140-6736(18)32534-0

39. Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017; 377:2113-2122. doi: 10.1056/NEJMoa1709038

40. Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319:1999-2008. doi: 10.1001/jama.2018.4853

41. Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75:1080-1088. doi: 10.1001/jamaneurol.2018.1212

42. Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38:1442-1454. doi: 10.1177/0333102418779543

43. Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91:e2211-e2221. doi: 10.1212/WNL.0000000000006640

44. Goadsby PJ, Dodick DW, Leone M, at al. Trial of galcanezumab in prevention of episodic cluster headache. N Engl J Med. 2019; 381:132-141. doi: 10.1056/NEJMoa1813440

45. Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397:51-60. doi: 10.1016/S0140-6736(20)32544-7

46. Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385:695-706. doi: 10.1056/NEJMoa2035908

47. Qulipta (atogepant). Package insert. AbbVie; 2021. Accessed June 19, 2023. www.accessdata.fda.gov/drugsatfda_docs/label/2021/215206Orig1s000lbl.pdf

48. Han L, Liu Y, Xiong H, et al. CGRP monoclonal antibody for preventive treatment of chronic migraine: an update of meta-analysis. Brain Behav. 2019;9:e01215. doi: 10.1002/brb3.1215

49. Zhu Y, Liu Y, Zhao J, et al. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol Sci. 2018;39:2097-2106. doi: 10.1007/s10072-018-3547-3

50. Szperka CL, VanderPluym J, Orr SL, et al. Recommendations on the use of anti-CGRP monoclonal antibodies in children and adolescents. Headache. 2018;58:1658-1669. doi: 10.1111/head.13414

51. Pellesi L, Do TP, Ashina H, et al. Dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale? Headache. 2020;60:1056-1065. doi: 10.1111/head.13843

52. D’Antona L, Matharu M. Identifying and managing refractory migraine: barriers and opportunities? J Headache Pain. 2019;20:89. doi: 10.1186/s10194-019-1040-x

53. Cohen F, Armand C, Lipton RB, et al. Efficacy and tolerability of calcitonin gene-related peptide targeted monoclonal antibody medications as add-on therapy to onabotulinumtoxinA in patients with chronic migraine. Pain Med. 2021;1857-1863. doi: 10.1093/pm/pnab093

54. Berman G, Croop R, Kudrow D, et al. Safety of rimegepant, an oral CGRP receptor antagonist, plus CGRP monoclonal antibodies for migraine. Headache. 2020;60:1734-1742. doi: 10.1111/head.13930

Ubrogepant, in 2 Phase 3 trials (ACHIEVE I and ACHIEVE II) demonstrated effectiveness compared with placebo.^21,22 The most common adverse effects reported were nausea and somnolence at very low rates. Pain-relief rates at 2 hours post dose (> 60% of participants) were higher than pain-free rates, and a significantly higher percentage (> 40%) of ubrogepant-treated participants reported ability to function normally on the Functional Disability Scale.²⁵

Rimegepant was also superior to placebo (59% vs 43%) in pain relief at 2 hours post dose and other secondary endpoints.²³ Rimegepant also has potential drug interactions and dose adjustments (TABLE 4^18-24).

Zavegepant, approved in March 2023, is administered once daily as a 10-mg nasal spray. In its Phase 3 trial, zavegepant was significantly superior to placebo at 2 hours post dose in freedom from pain (24% v 15%), and in freedom from the most bothersome symptom (40% v 31%).²⁴ Dosage modifications are not needed with mild-to-moderate renal or hepatic disease.²⁰

Worth noting. The safety of using ubrogepant to treat more than 8 migraine episodes in a 30-day period has not been established. The safety of using more than 18 doses of zavegepant in a 30-day period also has not been established. With ubrogepant and rimegepant, there are dosing modifications for concomitant use with specific drugs (CYP3A4 inhibitors and inducers) due to potential interactions and in patients with hepatic or renal impairment.^18,19

There are no trials comparing efficacy of CGRP antagonists to triptans. Recognizing that these newer medications would be costly, the AHS position statement released in 2019 recommends that gepants be considered for those with contraindications to triptans or for whom at least 2 oral triptans have failed (as determined by a validated patient outcome questionnaire).¹⁰ Step therapy with documentation of previous trials and therapy failures is often required by insurance companies prior to gepant coverage.

Continue to: Preventive therapies